Department of Pediatrics, University Hospital of Ioannina, Ioannina, Greece;
Pediatric Allergy and Respiratory Unit, 3rd Department of Pediatrics, "Attikon" University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Allergol Immunopathol (Madr). 2024 May 1;52(3):8-16. doi: 10.15586/aei.v52i3.1032. eCollection 2024.
Anaphylaxis proportions of incidence are increasing globally. However, limited data are available regarding anaphylaxis in the pediatric population of Greece.
The aim of the study was to evaluate management of anaphylaxis in Greek pediatric departments.
We performed a questionnaire-based study of children aged less than 16 years presenting with anaphylaxis in 10 national pediatric hospitals over a period of 2 years. Management of anaphylaxis was assessed prior to and after an informative intervention.
In all, 127 cases of anaphylaxis were identified. Epinephrine was administered in almost half of all cases (51.2%), predominantly through intramuscular route (88.5%), while the majority of anaphylaxis patients were treated with antihistamines (92.9%) and corticosteroids (70.1%). Epinephrine was more likely administered by physicians if the elicitor was a drug (P < 0.003). Regarding long-term management, an epinephrine auto-injector was prescribed in 66.9% of patients. Follow-up information was available for most of the patients (92.9%), the majority of whom (76.3%) were referred to an allergist. More than half of these patients (63.6%) had a documented allergy follow-up, which identified a causative allergen in 53.3% of cases. No statistically significant differences were recorded prior to and after the intervention regarding management of anaphylaxis.
This nationwide study highlighted the necessity of further improvement in terms of anaphylaxis treatment and secondary prevention measures. This presupposes appropriate education and training of healthcare professionals, thus contributing to proper and comprehensive care of the pediatric population.
全球范围内过敏反应的发病率呈上升趋势。然而，关于希腊儿科人群过敏反应的数据有限。
本研究旨在评估希腊儿科部门对过敏反应的管理。
我们对 10 家国家儿科医院在 2 年内出现过敏反应的 16 岁以下儿童进行了一项基于问卷调查的研究。在信息干预前后评估了过敏反应的管理情况。
共发现 127 例过敏反应病例。近一半的病例（51.2%）给予了肾上腺素，主要通过肌肉注射途径（88.5%），而大多数过敏反应患者接受了抗组胺药（92.9%）和皮质类固醇（70.1%）治疗。如果过敏原是药物，医生更有可能给予肾上腺素（P < 0.003）。关于长期管理，66.9%的患者开了肾上腺素自动注射器。大多数患者（92.9%）可获得随访信息，其中大多数（76.3%）被转介给过敏专家。这些患者中有一半以上（63.6%）有记录的过敏随访，其中 53.3%的病例确定了病因过敏原。干预前后在过敏反应的管理方面未记录到统计学上的显著差异。
这项全国性研究强调了进一步改善过敏反应治疗和二级预防措施的必要性。这需要对医疗保健专业人员进行适当的教育和培训，从而为儿科人群提供适当和全面的护理。
